. Analytic performances were determined in three laboratories. Clinical performances were evaluated on 100 plasma samples from HIV-2-infected patients (groups A, B, and H) by comparison with the assay currently used for the ANRS HIV-2 cohort. The specificity was 100%. Sensitivity was 50 copies/ml (cp/ml) and was optimized to 10 cp/ml. The within-run coefficients of variation in the three laboratories varied from 0.54% to 1.61% at 4 log 10 copies/ml and from 7.24% to 14.32% at 2 log 10 cp/ml. The between-run coefficients of variation varied from 2.28% to 6.43%. Of the 39 clinical samples below 2 log 10 in the current assay, the new test improved the detection or quantification of 17 samples, including eight group B samples. For quantifiable samples, similar loads were obtained with the two assays for group A samples. The median difference between the two assays for group B samples was ؉0.18 but with greater heterogeneity than for group A. The HIV-2 group H sample had similar results with the two assays. This new assay is highly sensitive and accurately quantifies the most prevalent HIV-2 groups. This test will be useful for monitoring low viral loads in HIV-2-infected patients.
H
IV-2 is characterized by less efficient transmission through the sexual and vertical routes than HIV-1 (1, 2) and by a slower natural clinical course (2-4); nevertheless, HIV-2 infection eventually leads to AIDS. HIV-2 infection must be distinguished from HIV-1 infection, as HIV-2 is naturally resistant to nonnucleoside reverse transcriptase inhibitors, T20, and some protease inhibitors, and as patient follow-up differs from that of HIV-1 infection (5, 6) .
Compared to HIV-1, HIV-2 is characterized by lower viral replication (4, (7) (8) (9) (10) . In the French National HIV-2 Cohort (974 patients in June 2013), 61% of untreated patients had plasma viral loads below 250 copies/ml (cp/ml). Likewise, in a British study, only 8% of patients with CD4 of Ͼ500 cells/mm 3 and 62% of patients with CD4 of Ͻ300 cells/mm 3 had detectable viral loads (11) , implying that 38% of patients had undetectable viral loads in an assay with a quantification limit of 100 copies/ml.
Clinical management of HIV-2 infection is hampered by the lack of validated commercial RNA viral load assays. In-house assays are therefore widely used (12) (13) (14) (15) (16) (17) (18) . The ACHI E V 2E international collaboration on HIV-2 infection showed that plasma HIV-2 RNA values vary considerably between laboratories (19, 20) . The high genetic diversity of HIV-2, with 9 groups designated A to I, of which only groups A and B are epidemic, also represents an obstacle to accurate viral load quantification (21) (22) (23) (24) (25) . Previous studies showed that group B viruses are particularly difficult to quantify (13, 19, 20) .
As most cases of HIV-2 infection occur in resource-limited settings, an affordable test is urgently needed, particularly to identify HIV-1/HIV-2 coinfection. The Agence Nationale de Recherche sur le Sida et les hépatites virales (ANRS) has previously promoted the development of an HIV-1 RNA assay, which is now marketed by Biocentric (Bandol, France) and is widely used in resource-limited settings (26, 27) . This test is easy to perform and affordable, and it has been proven to be useful for patient monitoring.
The aim of the present work was to develop a new sensitive method for quantifying HIV-2 RNA, particularly that of epidemic groups A and B. It is based on a one-step real-time duplex PCR method using the same amplification protocol as the Biocentric generic HIV-1 charge virale assay. The new test was compared with the HIV-2 assay currently used for the French HIV-2 cohort and was validated by three laboratories belonging to the ANRS AC11 quantification working group.
MATERIALS AND METHODS
The new HIV-2 RNA assay. The new test is based on a one-step duplex TaqMan PCR approach targeting a conserved consensus region in the long terminal repeat (LTR) region and the gag region. The forward and reverse primers for the LTR region are 5=-TCTTTAAGCAAGCAAGCGT GG-3= and 5=-AGCAGGTAGAGCCTGGGTGTT-3=, respectively (28) , with a new internal probe (5=-FAM-CTTGGCCGGYRCTGGGCAGA-BHQ1-3= [FAM, carboxyfluorescein; BHQ1, black hole quencher 1]) to optimize efficiency for HIV-2 group B. The forward and reverse primers for the gag region are F3 (5=-GCGCGAGAAACTCCGTCTTG-3=) and R1 (5=-TTCGCTGCCCACACAATATGTT-3=), respectively (13) , and the internal HIV-2 TaqMan gag probe is S65GAG2 (5=-FAM-TAGGTTACGG CCCGGCGGAAAGA-BHQ1-3= (Eurogentec, Seraing, Belgium) (13) .
RNA was extracted from 200 l of plasma by using the QIAamp viral RNA minikit (Qiagen, Courtaboeuf, France), as in the Biocentric generic HIV-1 charge virale assay, in labs A and B (Necker Hospital, Paris, and Charles Nicolle Hospital, Rouen) or 1 ml with the total nucleic acid (NA) large-volume MagNA Pure kit (Roche Automated System, Meylan, France) in lab C (Bichat Claude Bernard Hospital, Paris).
The reaction mix consists of a 20-l volume containing the RNA extract (10 l), primers (500 nM each), probes (250 nM each), and 1ϫ PCR buffer (4ϫ one-step mix; Invitrogen, Cergy-Pontoise, France).
The thermocycling conditions are those used for the Biocentric HIV-1 assay (10 min at 50°C and 5 min at 95°C, followed by 50 cycles of 95°C for 15 s and 60°C for 1 min). Amplification and data acquisition were carried out with the TaqMan ABI real-time PCR system (Applied Biosystems, Courtaboeuf, France). The log 10 number of targets initially present is proportional to the cycle threshold (C T ) and is determined from the standard curve.
A BIOQ HIV-2 RNA group A quantification panel (P0182; Rijswijk, the Netherlands) was used as the external standard. The standard, evaluated at 2.93 ϫ 10 6 cp/ml, was first diluted in RPMI culture medium to a theoretical concentration of 1,000,000 cp/ml (2,400,000 IU/ml), followed by serial 10-fold dilutions to concentrations ranging from 1,000,000 (5 log 10 ) to 100 cp/ml (2 log 10 ), and a final dilution to 40 cp/ml (1.6 log 10 ).
Determination of the analytic performance of the new assay. Specificity was determined by testing plasma samples from 49 HIV-negative subjects and 30 HIV-1 group M-positive patients with viral loads ranging from Ͼ20 to Ͻ10,000,000 cp/ml. Nine HIV-1 group O coculture supernatants were also tested.
Linearity was assessed using the BIOQ external standard diluted in RPMI to 1,000,000, 100,000, 10,000, 1,000, 100, and 40 cp/ml (each tested in 10 runs at lab A).
Analytical sensitivity was determined by dilution in RPMI of the BIOQ external standard to 100, 50, 40, 20, and 10 cp/ml (10 replicates each).
To determine within-run reproducibility, the BIOQ external standard was tested at concentrations of 10,000 and 100 cp/ml in each of the three laboratories (10 replicates for each dilution).
To determine between-run reproducibility, an HIV-2-positive control was prepared by serial dilution in HIV-negative EDTA human plasma of a coculture supernatant of an HIV-2 group A isolate (GenBank accession number AY688870). This solution was diluted to obtain aliquots with theoretical concentrations ranging from 10,000 to 100,000 cp/ml in the current assay. These aliquots were each tested once in 7 separate runs with the MagNA Pure automated extraction system (lab C) and in, respectively, 18 and 7 separate runs with Qiagen manual extraction at labs A and B.
Statistical analysis. MedCalc software (Ostend, Belgium) was used for data analysis. Bland and Altman curves were used to represent the degree of agreement between the two techniques (29) . The x axis bore the mean values for each sample obtained with the two techniques, and the y axis the difference between the values obtained with the two techniques.
Disagreement between the two techniques was defined as a difference of Ͼ0.5 log 10 for a given sample.
Clinical samples. One hundred plasma samples from HIV-2-infected patients (n ϭ 100) included in the French National HIV-2 Cohort (ANRS CO5) were selected according to the viral genotype and the HIV-2 RNA concentration, as determined with our current in-house technique (13) . Among these patients, 51% were treated by antiretrovirals. The HIV-2 group was determined for 89 samples, as previously described (22, 30) . Thirty-eight samples were group A, 50 group B, and 1 group H. Genotyping was not available for the remaining 11 samples, owing to the absence of detectable viral RNA and a lack of whole blood or mononuclear cells for viral DNA testing.
The selected samples had the following characteristics: Ͻ100 (2 log 10 ) cp/ml (n ϭ 39; 9 group A and 19 group B, 11 nongenotypable), 100 (2 log 10 ) to 1,000 (3 log 10 ) cp/ml (n ϭ 16; 5 A and 11 B), 1,000 (3 log 10 ) to 10,000 (4 log 10 ) (n ϭ 22; 12 A and 10 B), 10,000 (4 log 10 ) to 100,000 (5 log 10 ) (n ϭ 19; 11 A, 7 B, and 1 H) and Ͼ100,000 (5 log 10 ) (n ϭ 4; 1 A and 3B).
RESULTS
Analytic performances of the new assay. As expected, given the wide genomic divergence between HIV-1 and HIV-2, the HIV-2 primers did not hybridize to HIV-1 genes. All HIV-1-positive plasma samples and all HIV-negative samples were negative in the new assay, giving a specificity of 100%.
The standard curve showed a strong linear relationship between the C T values and log 10 HIV-2 RNA cp/ml (Fig. 1) . The median correlation coefficient was 0.9947 (range, 0.9831 to 0.9997), and the median slope was Ϫ3.37 (range, Ϫ3.16 to Ϫ3.62).
The analytical sensitivity of the assay was 100% at 40 cp/ml (1.6 log 10 cp/ml) and 90% at 20 cp/ml (1.3 log 10 cp/ml) after Roche MagNA Pure automated extraction of 1 ml and 100% at 50 cp/ml (1.7 log 10 cp/ml) after manual extraction of 200 l. Optimization of the assay sensitivity after manual extraction was evaluated using 1 ml of plasma. The sample was centrifuged at 17,000 rpm and the pellet was resuspended in 200 l of RPMI medium prior to manual extraction as previously described, with elution in 60 l. This yielded 90% sensitivity at 10 cp/ml (1 log 10 cp/ml).
Within-run reproducibility was evaluated in the three labs by using the BIOQ external standard with theoretical virus concentrations of 10,000 and 100 cp/ml (4 and 2 log 10 cp/ml). For the 4 log 10 cp/ml value, we obtained a mean of 3.91 log 10 cp/ml at lab C, 4.1 log 10 cp/ml at lab A, and 4.2 log 10 cp/ml at lab B, with withinrun coefficients of variation of 1.61%, 0.54%, and 1.10%, respectively. At the concentration of 2 log 10 cp/ml, we obtained mean values of 2.03 log 10 cp/ml at lab B, 2.07 log 10 cp/ml at lab A, and 2.17 log 10 cp/ml at lab C, with within-run coefficients of variation of 10.72%, 14.32%, and 7.24%, respectively.
In between-run assays, the positive control with a theoretical concentration between 10,000 (4 log 10 ) and 100,000 cp/ml (5 log 10 ) was evaluated at 4.61 log 10 cp/ml in lab C, 4.70 log 10 cp/ml in lab A, and 4.88 log 10 cp/ml in lab B, with coefficients of variation of 2.28%, 6.43%, and 3.03%, respectively.
Clinical performances. The clinical performances of the new assay were evaluated in lab C. Clinical samples of 1 ml were extracted with the automated MagNA Pure method, and then the same eluate was used to perform the two assays in parallel with the ABI device for the new assay and the Light Cycler 1.5 device for the current assay. The results obtained with the new assay were categorized into four groups (Table 1) , undetectable (Ͻ40 cp/ml), detectable but not quantifiable (0 to Ͻ40 cp/ml), quantifiable be-tween 40 and 100 cp/ml, and above the lower limit of quantification of the current assay (100 cp/ml).
Of the 39 samples below the quantification limit of 100 cp/ml in the current assay, 22 samples (56%) were also undetectable with the new assay (Table 1) , while 10 samples (26%; 3 A, 3 B, and 4 nongenotypable) were detected at values between 0 and 40 cp/ml (range, 1 to 36 cp/ml). Three samples (7.7%; 1 B and 2 nongenotypable) were quantified between 40 and 100 cp/ml (range, 56 to 79 cp/ml), and four samples (10%; all B) were quantified above 100 cp/ml (range, 102 to 970 cp/ml). The latter corresponded to true false-negative samples, taking into account the 100 cp/ml cutoff the current assay. These results showed that the new test improved the detection or quantification of 17/39 samples (43.6%), including eight group B samples (Table 1) .
All 61 plasma samples with values above 100 cp/ml in the current assay were detectable with the new test. One sample at 209 cp/ml (2.32 log 10 cp/ml) in the current assay gave a value of 46 cp/ml (1.69 log 10 cp/ml) in the new test (Table 1) .
A scatter plot was constructed with the values obtained for the 78 samples detectable or quantifiable with the new assay (Fig. 2) . It showed a wider dispersion of values for quantifiable group B samples than for quantifiable group A samples, as well as better detection or quantification of group B and nongenotypable samples. This was confirmed by scatter equations specific for group A samples (n ϭ 32; y ϭ 0.9485x ϩ 0.0294; r 2 ϭ 0.9619) and group B samples (n ϭ 39; y ϭ 0.7766x ϩ 0.8087; r 2 ϭ 0.8184) and also by Bland-Altman representations (Fig. 3) . Homogeneous quantification (Ϯ1.96 standard deviation [SD], range from Ϫ0.6 to 0.35) and similar values (median difference of Ϫ0.13) were obtained with the new and current assays for group A samples. The median difference between the two assays for group B samples was ϩ0.18, but with greater heterogeneity (Ϯ1.96 SD, range Ϫ0.98 to 1.33). No. of samples tested by current version of HIV-2 assay per indicated group at a VL (cp/ml) of: Ͻ100 cp/ml (2 log) (n ϭ 39) Ն100 cp/ml (2 log) (n ϭ 61)
Ͻ40 cp/ml (1.7 log) 6 11 5 0 to Ͻ40 cp/ml 3 3 4 40 Յ VL Ͻ 100 cp/ml 1 2 1 Ն100 cp/ml (2 log) Among the samples that were quantifiable with both assays, 10 samples showed differences above 0.5 log 10 , 9 of them belonging to group B. Five of these samples were better quantified with the new assay (differences of 0.53, 0.60, 0.68, 0.76, and 0.89 log 10 /ml) and five with the current assay (differences of 0.51, 0.52, 0.55, 0.66, and 0.70 log 10 /ml). These differences illustrate the difficulty of correctly assessing HIV-2 group B viral load.
The only HIV-2 group H sample gave very similar results with the two assays (4.33 log 10 and 4.34 log 10 ).
DISCUSSION
HIV-2 infection differs markedly from HIV-1 infection, notably by its slower natural course, different therapeutic management, and genetic diversity. Specific molecular methods are therefore necessary for diagnosis and patient monitoring. Current assays, mainly consisting of in-house methods or unvalidated derivatives of commercial kits, suffer from major limitations in terms of their sensitivity, accuracy, and coverage of HIV-2 genetic diversity (19, 20) .
The aim of this work was to develop a quantitative assay that takes into account both the low viral load seen in most HIV-2-infected patients and the broad genetic diversity of HIV-2, especially group B (13, 19, 20) . In addition, as most cases of HIV-2 infection occur in West Africa, such a test must be easy to implement in developing countries, as previously achieved with the generic HIV-1 viral load assay marketed by Biocentric.
We chose to optimize the assay currently used to monitor the French HIV-2 cohort based on amplification of the HIV-2 gag region, which gave accurate results in the ACHI E V 2E study (19, 20) , but with a lower limit of quantification of 100 cp/ml (13) and not completely adapted to some group B strains. We also used the same operating conditions as those of the Biocentric HIV-1 assay kit, in order to facilitate its use either for HIV-2 alone or jointly for HIV-1 and HIV-2.
The new test exhibits good linearity (40 to 1,000,000 cp/ml) and within-run reproducibility (Ͻ15%). Its interlaboratory reproducibility was validated by evaluation at three different sites. Both manual and automated extraction methods were validated for compatibility with local practices in resource-limited countries. Relative to the current assay, the new test has a significantly better analytical limit of quantification, reaching 50 cp/ml with manual extraction of 200 l of plasma and 40 cp/ml with automated extraction of 1 ml. Assuming a probit rate of 90%, the detection limits with 1 ml of plasma would be 10 cp/ml and 20 cp/ml, respectively. This very good analytical sensitivity matches that of recently published in-house methods (12, 14, 18) and is compatible with virological monitoring of HIV-2 infection, as Ͼ60% of untreated patients have viral loads below 250 cp/ml. The new test detected and/or quantified more than one-third of samples that were undetectable with our current assay, which has a quantification limit of 100 cp/ml. This excellent sensitivity should prove useful both for pathophysiological studies and for treatment monitoring.
FIG 2
Scatter diagram according to the genetic group of the 78 samples detectable (0 to Ͻ40 cp/ml) and quantifiable (Ն40 cp/ml) with the new assay (r 2 ϭ 0.8886). An arbitrary value of 20 cp/ml (1.3 log) was attributed to samples undetectable in the current assay, and to those detectable in the new assay (0 to Ͻ40 cp/ml). NA, nongenotypable samples. Bland and Altman curves for group A (top) (n ϭ 32) and group B (bottom) (n ϭ 39) samples detectable (0 to Ͻ40 cp/ml) and quantifiable (Ն40 cp/ml) with the new assay. An arbitrary value of 10 cp/ml was attributed to samples undetectable with the current assay, and 20 cp/ml to those detectable with the new assay (0 to Ͻ40 cp/ml).
The most difficult issue facing the development of HIV-2 viral load assays is the genetic diversity of this virus (especially group B), with some variants being underquantified or escaping detection with current tests (13, 19, 20) . Three teams recently reported improved sensitivity for HIV-2, but they mainly used supernatants (14) or a limited number of samples (12, 18) or validated detection but not quantification (18) , leaving questions as to their clinical performance, especially for group B viruses. We evaluated our new assay on 100 clinical samples, 39% of which were undetectable with our current assay, representative of the molecular epidemiology of groups A and B, plus the only one divergent sample of group H. Half the samples corresponded to group B, and more than one-third of them (n ϭ 19) were undetectable with our current assay. We chose to develop a duplex method capable of simultaneously amplifying the LTR and gag regions, in order to retain the benefits of each previous test and to improve the detection of group B viruses by reducing the risk of mismatches. Our strategy, based on coupling of primers and probes in two distinct regions of the viral genome, has already been adopted by Roche in version 2.0 of its CAP CTM HIV-1 assay, resulting in better quantification of HIV-1 non-B subtypes (31) . The new and current HIV-2 assay methods gave similar results for the single group H sample and for the group A samples (although 3 additional group A samples were detectable with the new test), whereas the new test developed by Delarue et al. gave values nearly 0.5 log 10 lower than their reference test (14) . Eight additional group B samples (42%) were detected or quantified with our new test, four samples having values of 102 to 970 cp/ml. This improvement is due to the addition of primers in the LTR region and to changes in the LTR probe (data not shown). However, the wider dispersion of values and the larger number of group B than group A samples with differences exceeding 0.5 log 10 relative to the current assay illustrate the greater difficulty of group B quantification. In addition, six nongenotypable samples were better detected or quantified with our new assay.
We designed the new test for use under the same operating conditions as the generic HIV-1 RNA assay currently used with success in many resource-limited countries (26, 27) , meaning it could be used on the same machine, with the same software program and even, if necessary, in the same amplification plate, as HIV-1 samples. This will reduce analytical costs by increasing the number of samples per run.
Although ours is an in-house assay, its performance is adequate for patient monitoring in the absence of a validated commercial test. In addition, the use of a standardized kit that includes an external standard will improve interlaboratory reliability, as shown by the 2nd International ACHI E V 2E study (19, 20) .
The analytical performance of our new assay is similar to that of other newly developed tests (12, 14, 18) . However, it is difficult to compare our method with the test described by Chang et al., adapted from the Abbott platform (Abbott Molecular, Chicago, IL), as the latter was evaluated on few group B samples and was not compared with other techniques (12). Styer et al. recently compared their method with this "Abbott" technique and observed a difference of Ϫ0.35 log 10 UI/ml, but they used a limited panel of uncharacterized samples, ruling out any evaluation of in terms of genetic diversity (18) . Finally, Delarue et al. (14) and Styer et al. (18) used two-step methods, whereas our assay is performed in a single step.
In conclusion, we have developed and standardized an assay with better analytical sensitivity than the technique currently used to monitor HIV-2-infected patients in France. Our assay also has improved clinical sensitivity and has been validated on a broad, well-characterized sample panel, unlike other recently published tests (12, 14, 18) . The analytical performance of this new assay, which is easy to perform, makes it suitable for use in resourcelimited countries in which multiple HIV-2 variants circulate. In addition, our assay can be used on the same analytical platforms and in the same run as tests for HIV-1, thus improving its costefficiency for monitoring patients infected with HIV-1 and/or HIV-2. This possibility of simultaneous analysis will facilitate molecular diagnosis of mother-to-child transmission of HIV-1 and/or HIV-2, and also diagnosis and follow-up of dual HIV-1/ HIV-2 infection in the same sample. Finally, use of this assay for virological monitoring will provide new insights into the natural history of HIV-2 infection at different clinical stages.
